Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the… Read More

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system… Read More

[Oct. 12, 2023: Staff Writer, The Brighter Side of News] Photo of U. of I. researchers. Illinois professor of veterinary clinical medicine Dr. Timothy Fan, left, and chemistry professor Pau… Read More

Peter Lucas Neurosurgeon says the human brain, with its intricate network of billions of neurons, is one of the most complex and vital organs in the body. Unfortunately, like any other part… Read More

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system… Read More

[Sept. 12, 2023: Diana Yates, University of Illinois at Urbana-Champaign] Photo of U. of I. researchers. Illinois professor of veterinary clinical medicine Dr. Timothy Fan, left, and chemist… Read More

The therapeutic areas of clinical research guide researchers, physicians, and biopharma companies in pursuing improved healthcare interventions and patient outcomes. The most common therapeu… Read More

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrat… Read More

What matters in cancer |  View this email in your browser Thursday 24 August 2023… Read More

MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June… Read More

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system… Read More

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous syst… Read More

Patients with aggressive brain tumours may be able to take part in a new trial of a cannabinoid-based drug, coordinated by the University of Birmingham. A major UK clinical trial of an oral… Read More

Introduction to HER and ADCs Members of the human epidermal growth factor receptor (HER) family, including HER1 (EGFR), HER2, HER3, and HER4, play a core role in regulating cell prolifera… Read More

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the live… Read More

“Orphan” drug status is offering these ASX pharma stocks a chance to turn a healthy profit – and give hope to those suffering rare conditions. Rare or “orphan&rd… Read More

What matters in cancer |  View this email in your browser Thursday 18 May 2023… Read More

Researchers from the University of Miami Miller School of Medicine recently developed a new AI algorithm that can perform advanced computational analysis. In doing so, possible therapeutic t… Read More

CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethic… Read More

International Women’s Day gives us all a chance to reflect on and celebrate the progress women have made in historically male-dominated fields, such as science, technology, engineering… Read More

T-cells are a type of white blood cell (lymphocyte), one of the primary components of the immune system. They fight cancer cells and foreign substances, such as viruses and bacteria. They de… Read More

(CTN NEWS) – DCVax – Global clinical trials have concluded that the world’s first vaccine to treat deadly cancerous brain tumours could extend patients’ lives by year… Read More

What matters in cancer |  View this email in your browser Thursday 12 January 2023… Read More

HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical tr… Read More

DelveInsight’s, “Glioma Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It cover… Read More

Researchers at the University of Toronto are inching closer to realizing a life-saving brain cancer treatment by using gold nanoparticles to make radiation therapy more effective and less… Read More

Aug 08, 2022 05:20 IST Washington [US], August 8 (Always First): Genetic signatures that can predict whether tumours in patients with bladder and other cancers will resp… Read More

Novartis’ Tafinlar and Mekinist received FDA approval for the treatment of unresectable or metastatic solid tumors with the BRAF V600E mutation. On Thursday, Tafinlar® (dabrafenib)… Read More

After releasing top-line results from an over 15-year study, NWBO stock fell 50% on Tuesday. Investors had high hopes for the study, and the presentation did not deliver. Northwest Biotherap… Read More

Market OverviewGlobal Glioblastoma Market is expected to register a CAGR of 7.40% to reach 1,643.4 million by 2025. Glioblastoma is a type of brain tumor. The increasing occur… Read More